McKesson (MCK) Q1 2027 (USD): Adj. EPS 9.93 (exp. 9.56), Revenue 105.4bln (exp. 103.9bln)

• Sees FY adj. EPS at 44.20-45.0 (exp. 44.26).

A beat on both lines with full-year guidance nudged above consensus fits the pattern this name has historically exhibited: drug distributors have tended to run a beat-and-raise cadence, with the street pricing in the raise more than the quarter itself. The channel that matters here is script volume and branded drug pricing, which flow through the distribution segment at thin but scale-driven margins, so revenue beats of modest size can still carry earnings leverage. The distinction worth drawing is between guidance raised on operational strength versus guidance raised because the prior bar was set conservatively, since the first tends to hold the multiple while the second fades after the initial move. Peer read-across to the other national distributors has been the established pattern on these prints, with the group trading as a block on reimbursement and opioid-litigation headlines as much as on quarterly numbers. The immediate follow-ons are the call commentary on GLP-1 volumes, the specialty and oncology franchise, and any update to the buyback cadence, which has been a meaningful support to per-share earnings in past cycles. The medical-surgical segment commentary is the other tell, having been the swing factor in prior quarters.